Elanco Animal Health Incorporated [NYSE:ELAN]: Analyst Rating and Earnings
Stock market traders frequently keep their eyes on what Wall Street experts as it relates to a potential investment. For Elanco Animal Health Incorporated [ELAN], the most recent analyst consensus recommendation available since its latest financial results for the quarter ending in December. On average, stock market experts give ELAN an Outperform rating. Its stock price has been found in the range of 28.00 to 37.61. This is compared to its latest closing price of $33.00.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Elanco Animal Health Incorporated [ELAN] is sitting at 2.43. This is compared to 1 month ago, when its average rating was 2.43.
For the quarter ending in Mar-19 Elanco Animal Health Incorporated [ELAN] generated $0.73 billion in sales. That’s 1.67% lower than the average estimate of $0.74 billion as provided by Wall Street analysts. The three indicators above suggest that on the whole, this stock is not presenting an attractive investment option, as there are too many red flags that don’t point to a high-value ROI.
Keep your eyes peeled for the soon-to-be-published financial results of this company, which are expected to be made public on Thu 8 Aug (In 83 Days).
Fundamental Analysis of Elanco Animal Health Incorporated [ELAN]
Now let’s turn to look at profitability: with a current Operating Margin for Elanco Animal Health Incorporated [ELAN] sitting at +10.23 and its Gross Margin at +42.25.
This company’s Return on Total Capital is 4.06, and its Return on Invested Capital has reached 2.00%. Its Return on Equity is 1.33, and its Return on Assets is 0.97. These metrics suggest that this Elanco Animal Health Incorporated does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
Turning to investigate this organization’s capital structure, Elanco Animal Health Incorporated [ELAN] has generated a Total Debt to Total Equity ratio of 47.57. Similarly, its Total Debt to Total Capital is 32.23, while its Total Debt to Total Assets stands at 27.60. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 47.01, and its Long-Term Debt to Total Capital is 31.86. This company has a healthy balance between its debt and its current holdings, suggesting it is a reliable investment due to its ability to leverage debt in an efficient way.
What about valuation? This company’s Enterprise Value to EBITDA is 22.91 and its Total Debt to EBITDA Value is 4.05. The Enterprise Value to Sales for this firm is now 4.56, and its Total Debt to Enterprise Value stands at 0.21. Elanco Animal Health Incorporated [ELAN] has a Price to Book Ratio of 2.22, a Price to Cash Flow Ratio of 20.30.
Shifting the focus to workforce efficiency, Elanco Animal Health Incorporated [ELAN] earns $530,588 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 4.68 and its Total Asset Turnover is 0.34. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 1.55 and its Current Ratio is 2.58. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Elanco Animal Health Incorporated [ELAN] has 365.64M shares outstanding, amounting to a total market cap of $12.07B. Its stock price has been found in the range of 28.00 to 37.61. At its current price, it has moved by -11.36% from its 52-week high, and it has moved 19.06% from its 52-week low.
This stock’s Beta value is currently , which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 58.48. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is Elanco Animal Health Incorporated [ELAN] a Reliable Buy?
Shares of Elanco Animal Health Incorporated [ELAN], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.